Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Blue Oak Pharmaceuticals is raising $9,000,130.00 in new funding. Sources indicate as part of senior management President, Thomas Large played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Blue Oak Pharmaceuticals

Blue Oak Pharmaceuticals is committed to finding the next generation of drugs for the brain disorders. We believe that first-in-class drugs will be discovered by integrating novel, custom-designed privileged chemotypes with validated in vivo systems neurobiology assays and brain circuit imaging. Blue Oak drug hunters are experts in the systems neurobiology of brain disorders, medicinal chemistry and informatics.  Our industry-leading productivity integrates a global research team that integrates established partners with cutting-edge technologies in behavioral profiling, synthetic chemistry and brain imaging.  We advance first-in-class clinical candidates to early phase proof-of-concept studies using translational medicine biomarkers for brain circuit activity.

To learn more about Blue Oak Pharmaceuticals, visit http://blueoakpharma.com/

Contact:
Thomas Large, President
317-331-8744
thomas.large@blueoakpharma.com
https://www.linkedin.com/in/tom-large-663b038/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved